Claritas Pharmaceuticals, Inc. (CLAZF)

Claritas Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Selling, General & Admin	1.57	1.87	3.66	3.35	3.13	3.45
Research & Development	-2.06	-2.06	5.79	7.75	1.67	1.62
Operating Expenses	-0.49	-0.18	9.45	11.1	4.8	5.07
Operating Income	0.49	0.18	-9.45	-11.1	-4.8	-5.07
Interest Expense	-2.93	-0.23	-0.21	-0.15	-0.01	-0.18
Currency Exchange Gain (Loss)	0.12	0.12	-0.27	0.05	-0.05	-0.01
Other Non Operating Income (Expenses)	2.71	2.71	0.52	14.02	-17.3	0.63
EBT Excluding Unusual Items	0.38	2.79	-9.41	2.82	-22.17	-4.63
Merger & Restructuring Charges	-	-	-	-	-0.11	-6.92
Asset Writedown	-15.63	-15.63	-33.77	-2.49	-	-
Other Unusual Items	12.17	12.17	17.34	6.51	-9.58	-
Pretax Income	-3.08	-0.67	-25.83	6.84	-31.86	-11.55
Income Tax Expense	-4.88	-4.88	-4.62	-0.1	-	-
Net Income	-4.72	4.21	-21.21	6.94	-31.86	-11.55
Net Income to Common	-4.72	4.21	-21.21	6.94	-31.86	-11.55
Shares Outstanding (Basic)	35	27	22	10	6	1
Shares Outstanding (Diluted)	35	27	22	11	6	1
Shares Change (YoY)	33.44%	18.94%	105.55%	75.89%	322.12%	39.75%
EPS (Basic)	-0.13	0.16	-0.95	0.71	-5.13	-7.86
EPS (Diluted)	-0.13	0.16	-0.95	-0.20	-5.20	-7.86
Free Cash Flow	-0.95	-0.31	-6.48	-4.85	-5.56	-1.64
Free Cash Flow Per Share	-0.03	-0.01	-0.29	-0.44	-0.90	-1.11
EBITDA	-	-	-	-	-4.78	-5.05
D&A For EBITDA	-	-	-	-	0.02	0.02
EBIT	0.49	0.18	-9.45	-11.1	-4.8	-5.07

Updated Nov 29, 2021. Source: S&P Global Market Intelligence. Standard template. Financial Sources.